BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carrat F, Nahon P, Duclos-Vallée JC, Pageaux GP, Fontaine H, Pol S; ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy". J Hepatol 2016;65:1269-70. [PMID: 27480588 DOI: 10.1016/j.jhep.2016.07.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Zarski J, David-tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret M, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-thoraval F, Nahon P. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2020;44:524-31. [DOI: 10.1016/j.clinre.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Russo FP, Bruno S, Farinati F. HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A “true-or-false game”. Digestive and Liver Disease 2017;49:321-5. [DOI: 10.1016/j.dld.2017.01.159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ramadori G, Bosio P, Moriconi F, Malik IA. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. BMC Cancer 2018;18:257. [PMID: 29510685 DOI: 10.1186/s12885-018-4175-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]